70 related articles for article (PubMed ID: 10994733)
1. Micronucleus yield and colorimetric test as indicators of damage in patients' lymphocytes after 131I therapy.
Catena C; Conti D; Trenta G; Righi E; Breuer F; Melacrinis FF; Montesano T; Ventroni G; Ronga G
J Nucl Med; 2000 Sep; 41(9):1522-4. PubMed ID: 10994733
[TBL] [Abstract][Full Text] [Related]
2. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay.
Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Futatsuya R; Michigishi T; Tonami N; Seto H; Goodwin DA
J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288
[TBL] [Abstract][Full Text] [Related]
3. Micronuclei and 3AB-index in patients receiving iodine-131 therapy.
Catena C; Villani P; Nastasi R; Conti D; Righi E; Salerno G; Righi VA; Ronga G
J Nucl Biol Med (1991); 1994 Dec; 38(4):586-93. PubMed ID: 7786922
[TBL] [Abstract][Full Text] [Related]
4. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
Pahlka RB; Sonnad JR
Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
[TBL] [Abstract][Full Text] [Related]
5. The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes.
Watanabe N; Kanegane H; Kinuya S; Shuke N; Yokoyama K; Kato H; Tomizawa G; Shimizu M; Funada H; Seto H
J Nucl Med; 2004 Apr; 45(4):608-11. PubMed ID: 15073256
[TBL] [Abstract][Full Text] [Related]
6. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis.
Joseph LJ; Bhartiya US; Raut YS; Kand P; Hawaldar RW; Nair N
Mutat Res; 2009 Apr; 675(1-2):35-40. PubMed ID: 19386245
[TBL] [Abstract][Full Text] [Related]
7. Glycophorin A as a biological dosimeter for radiation dose to the bone marrow from iodine-131.
Jensen RH; Reynolds JC; Robbins J; Bigbee WL; Grant SG; Langlois RG; Pineda JD; Lee T; Barker WC
Radiat Res; 1997 Jun; 147(6):747-52. PubMed ID: 9189175
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the reticulocyte micronucleus assay in patients treated with radioiodine for thyroid cancer.
Grawé J; Biko J; Lorenz R; Reiners C; Stopper H; Vershenya S; Vukicevic V; Hempel K
Mutat Res; 2005 May; 583(1):12-25. PubMed ID: 15866462
[TBL] [Abstract][Full Text] [Related]
10. 131I therapy of toxic and non-toxic goiters.
Beckers C
Q J Nucl Med; 1999 Dec; 43(4):291-6. PubMed ID: 10731779
[TBL] [Abstract][Full Text] [Related]
11. Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131.
Ballardin M; Gemignani F; Bodei L; Mariani G; Ferdeghini M; Rossi AM; Migliore L; Barale R
Mutat Res; 2002 Feb; 514(1-2):77-85. PubMed ID: 11815246
[TBL] [Abstract][Full Text] [Related]
12. Micronuclei frequency in peripheral blood lymphocytes of cancer patients: a meta-analysis.
Iarmarcovai G; Ceppi M; Botta A; Orsière T; Bonassi S
Mutat Res; 2008; 659(3):274-83. PubMed ID: 18582599
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy accelerates apoptosis in peripheral blood lymphocytes of patients with differentiated thyroid cancer.
Vrndic O; Milosevic-Djordjevic O; Djurdjevic P; Jovanovic D; Mijatovic L; Jeftic I; Simonovic SZ
Neoplasma; 2013; 60(5):568-75. PubMed ID: 23790177
[TBL] [Abstract][Full Text] [Related]
14. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
15. A minimally invasive method to evaluate 131I kinetics in blood.
Traino AC; Di Martino F; Boni G; Mariani G; Lazzeri M
Radiat Prot Dosimetry; 2004; 109(3):249-52. PubMed ID: 15254330
[TBL] [Abstract][Full Text] [Related]
16. The effects of a custom-made lead collar on dose rates of patients treated with 131I.
Stapel AG; van der Zant FM; Gommans GM; Boer RO; Reigman HI
Health Phys; 2009 May; 96(5 Suppl 2):S64-8. PubMed ID: 19359844
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
18. The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy.
Song EY; Rizvi SM; Qu CF; Raja C; Yuen J; Li Y; Morgenstern A; Apostolidis C; Allen BJ
Phys Med Biol; 2008 Jan; 53(2):319-28. PubMed ID: 18184988
[TBL] [Abstract][Full Text] [Related]
19. Micronuclei in peripheral blood from patients after cytostatic therapy mainly arise ex vivo from persistent damage.
Arsoy NS; Neuss S; Wessendorf S; Bommer M; Viardot A; Schütz P; Speit G
Mutagenesis; 2009 Jul; 24(4):351-7. PubMed ID: 19423564
[TBL] [Abstract][Full Text] [Related]
20. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
